No Data
Express News | Broncus Holding Corp FY Gross Profit USD 6.1 Million
BRONCUS-B: ANNOUNCEMENT OF ANNUAL RESULTSFOR THE YEAR ENDED DECEMBER 31, 2024ANDCHANGE IN USE OF NET PROCEEDS
AI empowers precision Medical, Kunbo Medical-B (2216.HK) BroncQCT opens a new era in lung diagnosis and treatment.
In the wave of Global digital transformation in Medical Care, AI is transforming from a technical Concept into clinical productivity. The reasoning capabilities of large models and their multimodal abilities are continuously upgrading, and application costs are constantly decreasing, driving Medical Institutions to accelerate the integration of AI technology, widely involving areas such as auxiliary diagnosis and medical imaging. Consequently, AI in Medical Care has become a major focus of attention. According to estimates by DataBridge, the market size of Generative AI in the field of Medical Care is expected to reach $17.2 billion by 2031, with a remarkable compound annual growth rate of 32.60% from 2023 to 2031. This number
Broncus Holding Gets Marketing Approval for Lung Imaging Software in China
Kunbo Medical-B (02216.HK): The lung imaging processing software BRONCQCT has been approved for launch in China.
On March 21, according to Gelonghui, Kunbo Medical-B (02216.HK) announced that its lung imaging processing Software BroncQCT (hereinafter referred to as "the Software") has officially been approved by the Zhejiang Provincial Pharmaceutical Administration for launch in China. The approval for this Software reflects the group's commitment to developing solutions that enhance clinical benefits, further solidifying the company's position in the field of precise intervention diagnosis and treatment of lung diseases. The Software is expected to improve doctors' efficiency in interpreting lung Computed Tomography (CT) images, providing strong support for clinical auxiliary diagnosis and treatment, and promoting a more efficient and precise diagnostic process.
Kunbo Medical-B (02216.HK) will hold a Board of Directors meeting on March 31 to approve the annual performance.
Gelonghui, March 19丨Kunbo Medical-B (02216.HK) announced that the Board of Directors will hold a meeting on March 31, 2025, to approve (including) the annual results of the company and its subsidiaries for the year ending December 31, 2024, and to propose the distribution of a final dividend (if any).
102768097 : how to do?